--- title: "Weekly Recap | Legend Biotech +8.18%, LB2501 shows 100% response rate" type: "News" locale: "en" url: "https://longbridge.com/en/news/304722892.md" description: "Legend Biotech (LEGN) gained 8.18% this week to close at $23.40, while the S&P 500 fell 2.68%, leaving the stock roughly 10.86 percentage points ahead of the benchmark. The week started with a dip to $20.99 on Monday, followed by four straight days of recovery. Volume picked up on Wednesday, and the stock hit a weekly high of $23.98 on Thursday before settling at $23.40 on Friday. The week’s amplitude was 13.73%, with average daily volume about 12.6% above the 5-day median." datetime: "2026-11-07T08:15:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/304722892.md) - [en](https://longbridge.com/en/news/304722892.md) - [zh-HK](https://longbridge.com/zh-HK/news/304722892.md) generator: "portal-rs" --- # Weekly Recap | Legend Biotech +8.18%, LB2501 shows 100% response rate ## The Week Legend Biotech (LEGN) gained 8.18% this week to close at $23.40, while the S&P 500 fell 2.68%, leaving the stock roughly 10.86 percentage points ahead of the benchmark. The week started with a dip to $20.99 on Monday, followed by four straight days of recovery. Volume picked up on Wednesday, and the stock hit a weekly high of $23.98 on Thursday before settling at $23.40 on Friday. The week’s amplitude was 13.73%, with average daily volume about 12.6% above the 5-day median. ## Key Events The main story this week was LB2501 clinical data and the ASH annual meeting schedule. After the close on 4 November, Legend disclosed that LB2501 showed a 100% complete response rate in eight patients at dose level 2; the stock climbed more than 6% intraday the next day. The company and parent GenScript followed with announcements that Legend will present cell-therapy data at the American Society of Hematology (ASH) 2026 annual meeting, including CAR-T research findings on multiple myeloma. On 6 November, attention turned to how ASH abstract acceptances might affect the stock. There were no material filings or non-routine disclosures this week. ## Analyst Ratings Among the 13 institutions covering Legend Biotech, 5 rate it buy, 5 rate it outperform, and 3 rate it hold, with no sell or underperform ratings. The consensus recommendation is buy, with a consensus target price of $45.62, about 95.0% above the current price. Target prices range from $24.00 to $68.00, showing wide dispersion. Within the biotech industry, Legend ranks 98th out of 510 companies in terms of rating coverage, while the industry median is 6 institutions. ## The Week Ahead Legend Biotech reports Q3 FY2026 results on Tuesday, 10 November, with consensus estimates at $0.0118 EPS on $360 million in revenue. The same day brings US CPI and core CPI data, with core CPI at 2.6 prior and 2.8 forecast, which may shift risk appetite. On Monday, 9 November, US wholesale sales data are due. The company’s FY2026 annual results are scheduled for 10 March 2027. ## In Short The stock’s gains this week coincided with the LB2501 complete response data and ASH presentation schedule, while the analyst setup remains broadly positive with a consensus target well above spot. The latest trading day showed large-lot money as a net buyer, but medium and small flows diverged, and the company remains loss-making on a valuation basis. The near-term focus is on Q3 results and further ASH abstract momentum, alongside how CPI data shapes overall risk appetite. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md) ## Related News & Research - [How ASH Abstract Acceptances Will Impact Legend Biotech Stock (LEGN)](https://longbridge.com/en/news/304646665.md) - [Legend Biotech's LB2501 Shows 100% Complete Response Rate in Eight Patients at Dose Level 2](https://longbridge.com/en/news/304290227.md) - [Legend Biotech to Present Cell-Therapy Data at ASH 2026](https://longbridge.com/en/news/304362764.md) - [What Is Drawing Attention To Legend Biotech (LEGN)?](https://longbridge.com/en/news/302964375.md) - [RBC Capital Sticks to Its Buy Rating for Legend Biotech (LEGN)](https://longbridge.com/en/news/298668225.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**